Eupraxia PharmaceuticalsEPRX
13F holders, Q3 2024 (September 30)8holders
3new positions
3sold out
$2.53avg. 13F price*
At the end of Q3 2024, 8 institutions reported holding Eupraxia Pharmaceuticals Inc. (EPRX) in their 13F filings, unchanged from Q2 2024. 3 opened new positions and 3 sold out. The largest holders were Scotia Capital Inc. ($3.5M), Royal Bank of Canada ($714K) and Bank of Montreal ($126K).
- Company
- Eupraxia Pharmaceuticals Inc.
- CUSIP
- 29842P105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $95K |
| Exits | 3 | $7K |
All 13F filers, Q2 2024 → Q3 2024: 74,333 shares bought and 2,555 shares sold, net +71,778 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Scotia Capital Inc. | 0.02% | Add +2.1% | 1,396,281 | $3.5M |
| Royal Bank of Canada | 0.00% | Add +2.1% | 271,287 | $714K |
| Bank of Montreal | 0.00% | No change | 49,250 | $126K |
| Goldman Sachs Group Inc. | 0.00% | New | 34,500 | $91K |
| UBS Group AG | 0.00% | Add +11.5% | 33,000 | $87K |
| 180 Wealth Advisors, LLC | 0.01% | No change | 13,000 | $34K |
| TD Waterhouse Canada Inc. | 0.00% | New | 1,500 | $4K |
| National Bank of Canada | 0.00% | New | 150 | $394 |
"% of holder's portfolio" is EPRX's weight in each manager's 13F, not the share of Eupraxia Pharmaceuticals Inc. the manager owns.